How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?

For instance, how would you manage a patient with both EGFR L858R and EGFR A647T mutations? Additionally, does the presence of brain metastasis influence your treatment strategy?

1 Answer

Mednet MemberInvited Expert

Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

Answered on · Updated on

I was asked to dust off q prior Mednet discussion on frontline treatment selection for patients with a new diagnosis of advanced common EGFR mutation+ NSCLC in light of recent updates on both the key FLAURA2 and MARIPOSA trials. And indeed the timing seems ripe for such not just due to these updates...

Join for free or sign in to see the full answer